GeoVax Executives to Advance Vaccine Partnerships at European Conferences

GeoVax Labs, Inc. senior leadership will participate in key European meetings over the coming weeks to advance partnering and collaboration engagement across the company's portfolio of multi-antigen vaccines and immunotherapies for infectious diseases and cancer. Chairman and Chief Executive Officer David A. Dodd and Vice President John Sharkey, PhD, together with other senior team members, will attend and host meetings at World Vaccine Congress Europe 2025 in Amsterdam from October 14-16 and BIO-Europe 2025 Fall in Vienna from November 3-5.

In addition to conference activities, the team will conduct meetings with global non-governmental organizations including WHO, UNICEF, CEPI, Gavi, and the Africa CDC, as well as established and prospective academic institutional collaborators across Europe. David A. Dodd emphasized the company's focus on solidifying durable relationships that can accelerate development in support of expanded access to critical vaccines and immunotherapies. The engagement with global health leaders and prospective partners aims to align on near-term opportunities in mpox and smallpox preparedness, addressing the critically unmet needs of immunocompromised patients relative to COVID-19, expanding the development breadth of Gedeptin as neoadjuvant cancer therapy, and exploring complementary collaborations across the broader platform.

GeoVax will highlight opportunities spanning its pipeline and technology platforms, including the GEO-MVA mpox and smallpox vaccine candidate, which represents a U.S.-based MVA program designed to accelerate access to a second-source of the critically needed vaccine and rapid, scalable MVA manufacturing. The company's GEO-CM04S1 multi-antigen COVID-19 vaccine is designed to elicit robust T-cell and antibody responses, with partnering priorities focused on addressing the current unmet needs of an estimated over 400 million immunocompromised patients worldwide. Gedeptin, a tumor-targeted immuno-oncology approach, shows potential combination synergies with checkpoint inhibitors, providing a potential new neoadjuvant therapy against solid tumors.

The broader MVA platform applications include hemorrhagic fever and Zika programs, continuous cell-line manufacturing, and potential technology-transfer collaborations. Dr. John Sharkey noted that the company continues to receive compelling interest from governments, NGOs, and potential industry collaborators seeking diversified, resilient vaccine supply and clinically differentiated immunotherapies. The goal is to convert that interest into structured collaborations that accelerate development, manufacturing readiness, and regional availability. Additional information about GeoVax and its programs is available at https://www.geovax.com.